In the study of Hosseinpour-Arjmand S. et al., there was also a significant decrease in the serum concentration of IL-6 in obese patients with non-alcoholic fatty liver disease who received orally 1200 mg ALA per day for 12 weeks (n = 23) in comparison with the placebo group (n = 22) [16]. Here, IL6 is linked to alcoholic fatty liver disease.